C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Provided By GlobeNewswire
Last update: Oct 31, 2024
Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA
Read more at globenewswire.comNASDAQ:CCCC (9/8/2025, 12:21:09 PM)
2.635
-0.09 (-3.13%)
Find more stocks in the Stock Screener
